eFFECTOR is developing a novel class of small molecule drugs to selectively regulate translation (protein synthesis) with an initial emphasis on cancer. The company has two candidate molecules in clinical trials and a partnership with Pfizer. Kevan Shokat, ex-Intellikine (a portfolio company that Abingworth exited successfully in 2012), is one of the scientific founders. In August 2021 the company merged with Locust Walk Acquisition Corp. and listed on the Nasdaq under the ticker EFTR.